妊娠期接种RSVpreF疫苗获批后早期序贯安全性监测
该研究采用序贯监测设计,利用5个研究伙伴的健康计划数据,分析2024年4月25日至2025年4月10日间5个序贯监测期,纳入孕32周及以上、活产或死产的15-54岁孕妇。暴露组为2023年9月22日至2024年8月9日接种RSVpreF者(13619例),对照为同期接种流感、COVID-19和/或Tdap疫苗者及2018年9月1日至2023年1月31日历史对照。主要结局为早产和妊娠相关高血压疾病。早产风险未升高(同期对照ARR 0.79,95%CI 0.65-0.98;历史对照ARR 0.87,95%CI 0.78-0.96)。自第二监测期起,妊娠相关高血压疾病(同期对照ARR 1.14,95%CI 1.02-1.27;历史对照ARR 1.29,95%CI 1.24-1.34)、胎膜早破(历史对照ARR 1.14,95%CI 1.09-1.19)和早产胎膜早破(历史对照ARR 1.18,95%CI 1.08-1.29)风险显著升高。结论认为不能排除上述风险可能升高,需进一步流行病学研究。
要点
- 妊娠期接种RSVpreF疫苗后早产风险未升高:同期对照ARR 0.79(95%CI 0.65-0.98),历史对照ARR 0.87(95%CI 0.78-0.96)。
- 自第二监测期起妊娠相关高血压疾病风险显著升高:同期对照ARR 1.14(95%CI 1.02-1.27),历史对照ARR 1.29(95%CI 1.24-1.34)。
- 胎膜早破风险在历史对照中显著升高(ARR 1.14,95%CI 1.09-1.19),同期对照未达统计学显著(ARR 1.09,95%CI 0.97-1.22)。
- 早产胎膜早破风险在历史对照中显著升高(ARR 1.18,95%CI 1.08-1.29)。
- 作者结论认为不能排除妊娠相关高血压疾病、胎膜早破和早产胎膜早破的风险可能升高,需进一步流行病学研究。
适用人群与场景
- 纳入15至54岁、妊娠达32周且以活产或死产结束的孕妇。
- 暴露组为2023年9月22日至2024年8月9日接种RSVpreF者;同期对照为接种流感、COVID-19和/或Tdap疫苗但未同时接种RSVpreF者;历史对照为2018年9月1日至2023年1月31日接种者。
- 暴露或对照疫苗接种时间为妊娠32至36周。
研究设计与关键结果
- 研究设计:采用序贯监测设计的队列研究,使用5个研究伙伴的健康计划数据,分析2024年4月25日至2025年4月10日间5个序贯监测期。
- 暴露组纳入13619例RSVpreF暴露妊娠,母亲平均(SD)年龄33.3(4.6)岁。
- 最常见安全性结局为妊娠相关高血压疾病(粗发生率17.3%,95%CI 16.6%-17.9%)和胎膜早破(粗发生率14.1%,95%CI 13.5%-14.7%)。
- 早产风险未升高:同期对照ARR 0.79(95%CI 0.65-0.98),历史对照ARR 0.87(95%CI 0.78-0.96)。
- 自第二监测期起,妊娠相关高血压疾病风险显著升高:同期对照ARR 1.14(95%CI 1.02-1.27),历史对照ARR 1.29(95%CI 1.24-1.34)。
- 自第二监测期起,胎膜早破风险在历史对照中显著升高(ARR 1.14,95%CI 1.09-1.19),同期对照未达统计学显著(ARR 1.09,95%CI 0.97-1.22)。
- 自第二监测期起,早产胎膜早破风险在历史对照中显著升高(ARR 1.18,95%CI 1.08-1.29)。
- 未观察到其他风险升高。
证据类型、等级与局限
- 证据类型:采用序贯监测设计的队列研究。
- 局限:因获批后早期可获得的混杂控制有限,不能排除妊娠相关高血压疾病、胎膜早破和早产胎膜早破的风险可能升高;需进一步流行病学研究以细化风险估计并纳入其他混杂因素。
对床旁实践的改变
- 作者认为,妊娠期接种RSVpreF疫苗与早产无关联;但不能排除妊娠相关高血压疾病、胎膜早破和早产胎膜早破的风险可能升高,需进一步流行病学研究。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Respiratory syncytial virus (RSV) is a leading cause of infant hospitalizations. In August 2023, the US Food and Drug Administration approved a bivalent RSV prefusion F subunit-based vaccine (RSVpreF) for maternal immunization to protect newborns. Sequential surveillance analysis provides information on the safety of a vaccine during its initial uptake.
OBJECTIVE: To report the sequential surveillance findings for 10 prespecified safety outcomes of exposure to RSVpreF during pregnancy over the course of its first vaccination season in the US.
DESIGN, SETTING, AND PARTICIPANTS: This cohort study with a sequential surveillance design used health plan data from 5 research partners. Health insurance data were analyzed across 5 sequential surveillance periods from April 25, 2024, through April 10, 2025. Pregnancies of individuals aged 15 to 54 years that culminated in a live birth or stillbirth and reached 32 gestational weeks were included. Cohorts included pregnancies exposed to RSVpreF (between September 22, 2023, and August 9, 2024); comparator pregnancies receiving influenza, COVID-19, and/or Tdap (tetanus, diphtheria, and acellular pertussis) vaccines but not the RSVpreF concurrently; and historical comparator pregnancies (vaccinated between September 1, 2018, and January 31, 2023).
EXPOSURE: RSVpreF or comparator vaccines (influenza, COVID-19, and/or Tdap but not RSVpreF) between 32 through 36 weeks' gestation.
MAIN OUTCOMES AND MEASURES: Primary outcomes were preterm birth and pregnancy-associated hypertensive disorders (composite of gestational hypertension; preeclampsia; eclampsia; hemolysis, elevated liver enzymes, and low platelet syndrome; or preexisting hypertension superimposed with preeclampsia or eclampsia). Secondary outcomes included premature rupture of membranes (PROM), preterm labor without preterm delivery, preterm PROM, maternal Guillan-Barré syndrome, and stillbirth. Infant outcomes were large for gestational age, small for gestational age, and low birth weight. Crude incidence proportions (IPs) and adjusted relative risks (ARR) were identified for these outcomes.
RESULTS: Among the 13 619 RSVpreF-exposed pregnancies included in the analysis, the mean (SD) maternal age was 33.3 [4.6] years. The most common safety outcomes were pregnancy-associated hypertensive disorders (IP, 17.3%; 95% CI, 16.6%-17.9%) and PROM (IP, 14.1%; 95% CI, 13.5%-14.7%). Risk of preterm birth was not elevated compared with the concurrent comparator (ARR, 0.79; 95% CI, 0.65-0.98) or historical comparator (ARR, 0.87; 95% CI, 0.78-0.96). Beginning with the second surveillance period, statistically significantly elevated risks were detected for pregnancy-associated hypertensive disorders (concurrent comparator: ARR, 1.14 [95% CI, 1.02-1.27]; historical comparator: ARR, 1.29 [95% CI, 1.24-1.34]), PROM (concurrent comparator: ARR, 1.09 [95% CI, 0.97-1.22]; historical comparator: ARR, 1.14 [95% CI, 1.09-1.19]), and preterm PROM (historical comparator: ARR, 1.18; 95% CI, 1.08-1.29). No other increased risks were observed.
CONCLUSIONS AND RELEVANCE: In this study using a sequential surveillance design, there was no association between RSVpreF vaccination during pregnancy and preterm birth; however, potential increased risks of pregnancy-associated hypertensive disorders, PROM, and preterm PROM could not be ruled out, due to limited confounding control available in the early postlicensure period. Further epidemiological studies are needed to refine risk estimates and account for other confounding factors.
参考来源
- Michnick AI, MacDonald SC, Adimadhyam S, et al. Sequential Safety Surveillance of RSVpreF Vaccination During Pregnancy Early in the Postapproval Period. JAMA Netw Open. 2026. PMID: 42012833. doi:10.1001/jamanetworkopen.2026.6190
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。